Logiscreen

Personalis Inc

$10.75
Market Cap 1.12B
ROE -43.5%
Gross Margin 1.8%
Debt/Equity 0.1
Current Ratio 6.6
Revenue QoQ -24.9%
EPS QoQ 0.6%
F-Score 2

About

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California.

Exchange
NASDAQ
Sector
Healthcare
Industry
Diagnostics & Research

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-13.25
vs median 31.50
P/B
4.97
vs median 2.17
ROE
-0.44
vs median 0.09

Lower quality - review fundamentals carefully

Small-cap company with higher volatility

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics